125MO Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
- Resource Type
- Abstract
- Authors
- Inoue, K.; Masuda, N.; Takano, T.; Ito, M.; Tanabe, Y.; Kawaguchi, K.; Yasojima, H.; Bando, H.; Nakamura, R.; Yamanaka, T.; Ishida, K.; Argua, T.; Yanagita, Y.; Tokunaga, E.; Aogi, K.; Ohno, S.; Kasai, H.; Kataoka, T.R.; Morita, S.; Toi, M.
- Source
- In ESMO Open May 2023 8(1) Supplement 4
- Subject
- Language
- ISSN
- 2059-7029